QLS31905 + pembrolizumab + capecitabine + oxaliplatin

This is an experimental **combination therapy** for advanced solid tumors, specifically targeting Claudin18.2-positive cancers. The regimen includes: - **QLS31905**: a monoclonal antibody targeting Claudin18.2, under clinical investigation for gastrointestinal and Claudin18.2-positive tumors[3][5][7]. - **Pembrolizumab**: an immune checkpoint inhibitor (anti-PD-1 antibody) approved for multiple cancers, which enhances anti-tumor immunity[2][6]. - **Capecitabine**: an oral prodrug of 5-fluorouracil (5-FU) used as a chemotherapy agent primarily for gastrointestinal cancers. - **Oxaliplatin**: a platinum-based chemotherapy agent, commonly used for colorectal and GI cancers. The combination is administered to patients with **Claudin18.2-positive advanced solid tumors**, including gastric/gastroesophageal junction cancer, aiming to improve outcomes by targeting the tumor antigen (Claudin18.2), reactivating host immunity (PD-1 blockade), and direct cytotoxic chemotherapy[1][7].

Brand names

pembrolizumab (KEYTRUDA)capecitabine (Xeloda)

Other names

QLS31905QLS-31905QLS 31905pembrolizumabcapecitabineoxaliplatin